Globe Newswire03.20.20
Daxor Corporation has announced the first use of its BVA-100 test to guide volume treatment in a patient infected with the COVID-19 virus. The company also announced the release of a clinical protocol for fluid guidance when utilizing the BVA-100 diagnostic test for COVID-19 patients developed by leading medical experts.
Dr. Henry Cremisi, a lead author on the clinical protocol titled, “A Protocol for Volume-Guided Therapy for Critical Care of COVID-19 Patients,” commented, “In my clinical experience, BVA has been most useful in circumstances that are challenging with respect to volume management, as well as disorders of oxygen-carrying status including anemias and polycythemia. In the particular setting of multi-organ system failure, the applied utility of BVA can be the difference between life and death.”
Reducing Mortality
“Optimal volume management and knowledge of capillary status is key to survivability, preventing collapse of the circulatory system and allowing time to defeat infection,” said Michael Feldschuh, CEO of Daxor Corporation. “The BVA-100 test has been shown in a prospective randomized control trial to reduce ICU mortality by as much as 66% and reduce ventilator days in patient populations suffering predominantly from respiratory distress and septic shock. In addition, we believe our test can have a significant impact on patient triage and help guide precise administration of scarce resources such as ventilators for our healthcare system because of its unique measure of capillary permeability, which has been shown to have important prognostic value in ICU outcomes.”
Soren Thompson, Daxor’s VP of Business Development stated, “We are fully supporting hospitals which have BVA devices on-site, as well as placement of new devices from our inventory in response to this urgent crisis.”
Daxor has launched a dedicated web page for healthcare professionals to access the protocol and learn more about the benefits of blood volume analysis in COVID-19 patients.
Dr. Henry Cremisi, a lead author on the clinical protocol titled, “A Protocol for Volume-Guided Therapy for Critical Care of COVID-19 Patients,” commented, “In my clinical experience, BVA has been most useful in circumstances that are challenging with respect to volume management, as well as disorders of oxygen-carrying status including anemias and polycythemia. In the particular setting of multi-organ system failure, the applied utility of BVA can be the difference between life and death.”
Reducing Mortality
“Optimal volume management and knowledge of capillary status is key to survivability, preventing collapse of the circulatory system and allowing time to defeat infection,” said Michael Feldschuh, CEO of Daxor Corporation. “The BVA-100 test has been shown in a prospective randomized control trial to reduce ICU mortality by as much as 66% and reduce ventilator days in patient populations suffering predominantly from respiratory distress and septic shock. In addition, we believe our test can have a significant impact on patient triage and help guide precise administration of scarce resources such as ventilators for our healthcare system because of its unique measure of capillary permeability, which has been shown to have important prognostic value in ICU outcomes.”
Soren Thompson, Daxor’s VP of Business Development stated, “We are fully supporting hospitals which have BVA devices on-site, as well as placement of new devices from our inventory in response to this urgent crisis.”
Daxor has launched a dedicated web page for healthcare professionals to access the protocol and learn more about the benefits of blood volume analysis in COVID-19 patients.
